Development of sarcoidosis during etanercept therapy

Arthritis Care and Research

Volumn 55, Issue 5, 2006, Pages 817-820

  González López, Marcos A ^a   Blanco, Ricardo ^a   Carmen Gonzalez Vela M ^a   Fernández Llaca, Héctor ^a   Rodríguez Valverde, Vicente ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ANKYLOSING SPONDYLITIS; ARTICLE; CASE REPORT; COUGHING; CROHN DISEASE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEVER; GIANT CELL ARTERITIS; GRANULOMATOUS INFLAMMATION; HEMATOCHEZIA; HISTOPATHOLOGY; HUMAN; IMMUNOSCINTIGRAPHY; LUNG NODULE; LYMPHADENOPATHY; MALE; PLEURA EFFUSION; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SKIN DEFECT; SKIN GRANULOMA; WEIGHT REDUCTION;

AGED; ANTIRHEUMATIC AGENTS; CYTOKINES; GRANULOMA; HUMANS; IMMUNOGLOBULIN G; MALE; NEOPLASM PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SARCOIDOSIS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 33750374622     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.22238     Document Type: Article

References (20)

1. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005;34 Suppl 1:7-11.
2. Keystone EC. The utility of tumour necrosis factor blockade in orphan diseases. Ann Rheum Dis 2004;63 Suppl 2:ii79-83.
3. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-71.
4. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124:177-85.
5. Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003;30:1864-7.
6. Hobbs K. Chronic sarcoid arthritis treated with intraarticular etanercept [letter]. Arthritis Rheum 2005;52:987-8.
7. Vavricka SR, Wettstein T, Speich R, Gaspert A, Bachli EB. Pulmonary granulomas after tumour necrosis factor α antagonist therapy. Thorax 2003;58:278-9.
8. Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest 2002;122:1858-60.
9. Phillips K, Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum 2005;53:618-20.
10. Hubscher O, Re R, Iotti R. Pulmonary rheumatoid nodules in an etanercept-treated patient [letter]. Arthritis Rheum 2003; 48:2077-8.
11. Kekow J, Welte T, Kellner U, Pap T. Development of rheumatoid nodules during anti-tumor necrosis factor α therapy with etanercept [letter]. Arthritis Rheum 2002;46:843-4.
12. Cunnane G, Warnock M, Fye KH, Daikh DI. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum 2002;47:445-9.
13. Seton M. Giant cell arteritis in a patient taking etanercept and methotrexate [letter]. J Rheumatol 2004;31:1467.
14. Oh J, Arkfeld DG, Horwitz DA. Development of Crohn's disease in a patient taking etanercept. J Rheumatol 2005;32:752-3.
15. Comité de Expertos de la SER. Actualización de la Conferencia de Consenso de la Sociedad Española de Reumatología sobre terapia anti-TNF en Artritis Reumatoide. Rev Esp Reumatol 2002;29:51-5.
16. Ziegenhagen MW, Muller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 2003;253:18-30.
17. Stucki G, von Felten A, Speich R, Michel BA. Ankylosing spondylitis and sarcoidosis: coincidence or association? Case report and review of the literature. Clin Rheumatol 1992;11:436-9.
18. Judson MA. The etiologic agent of sarcoidosis: what if there isn't one? Chest 2003;124:6-8.
19. Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol Suppl 2005;74:35-9.
20. Dinarello CA. Differences between anti-tumor necrosis factor-α monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl 2005;74:40-7.